Skip to main content

Table 2 Treatment characteristics

From: Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

  All patients (n = 30) Castrate-resistant (n = 11) Castrate-sensitive (n = 19)
Target volume   
Whole gland therapy 17 (57%) 11 (100%) 6 (32%)
Focal salvage therapy 13 (43%) 0 (0%) 13 (68%)
LHRH agonist    
Initiated with salvage SBRT (for 6 months) 15 (50%)   15 (79%)
Continued with salvage SBRT 11 (100%) 11 (100%)  
2nd generation anti-androgen    
Initiated with salvage SBRT    1 (5%)
Continued with salvage SBRT1   1 (9%)  
Rectal sparing   
Endo-rectal balloon 22 (73%) 7 (64%) 15 (79%)
Hydrogel spacer 8 (27%) 4 (36%) 4 (21%)
Urethral sparing   
Yes 17 (57%) 3 (27%) 14 (74%)
Prostate dose/fraction (Gy)
Median (range) 6.5 (6–8) 6.25 (6–7.25) 6.5 (6–8)
Number of fractions 5 5 5
Pelvic lymph nodes irradiation
Given in2 7 (23%) 3 (27%) 5 (26%)
  1. SBRT, salvage stereotactic body radiation therapy; Gy, gray; LHRH, luteinizing hormone-releasing hormone
  2. 1Castrate-resistant patients
  3. 2Dose for nodal SBRT was 25 Gy in 5 fractions